248
Participants
Start Date
July 7, 2020
Primary Completion Date
September 11, 2024
Study Completion Date
September 13, 2028
Surpass Evolve Flow Diverter System
The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
Sir Charles Gairdner Hospital, Nedlands
Gold Coast Hospital & Health Service/ Gold Coast University Hospital, Southport
ICAHN School of Medicine at Mount Sinai, New York
Stony Brook, Stony Brook
University of Buffalo, Buffalo
Geisinger Clinic, Wilkes-Barre
Thomas Jefferson University, Philadelphia
Virginia Commonwealth University, Richmond
Lyerly Baptist, Inc./Baptist Medical Center - Jacksonville/Lyerly Neurosurgery, Jacksonville
Mayo Clinic Florida, Jacksonville
Tallahassee Neurological Clinic, Tallahassee
Baptist Hospital of Miami, Miami
Semmes Murphey Clinic/ University of Tennessee Health Sciences Center, Memphis
Baptist Healthcare System, Inc./Baptist Health, Lexington
Cleveland Clinic, Cleveland
Indiana University, Indianapolis
Spectrum Health, Grand Rapids
University of Iowa, Iowa City
Advocate Lutheran General Hospital, Park Ridge
University of Kansas Medical Center, Kansas City
Montefiore Medical Center, The Bronx
University of Texas Medical Branch, Galveston
Valley Baptist Health System, Harlingen, Harlingen
University of Utah, Salt Lake City
DIGNITY HEALTH/ Barrow Neurological Institute, Phoenix
St. Joseph's Hospital, Tucson
University of California, Los Angeles, Los Angeles
Oregon Health & Science University, Portland
Maine Medical Center, Portland
Tufts Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Lahey Clinic, Burlington
University of Massachusetts, North Worcester
Robert Wood Johnson University Medical Center, New Brunswick
Liverpool Hospital, Liverpool
St. Michael's Hospital - Toronto, Toronto
University Health Network/ Toronto Western Hospital, Toronto
Stryker Neurovascular
INDUSTRY